A Phase 1 Study of SGN-ALPV in Advanced Solid Tumors
Latest Information Update: 13 Feb 2025
At a glance
- Drugs SGN-ALPV (Primary)
- Indications Carcinoma; Cervical cancer; Endometrial cancer; Gastric cancer; Germ cell cancer; Non-small cell lung cancer; Ovarian cancer; Solid tumours; Testicular cancer
- Focus Adverse reactions
- Sponsors Seagen
- 22 Dec 2023 Status changed from active, no longer recruiting to discontinued.
- 13 Oct 2023 Status changed from recruiting to active, no longer recruiting.
- 14 Jun 2023 Planned number of patients changed from 285 to 305.